Editor’s note: A livestream of the event is embedded below
Last summer Intellia reported the first data showing that CRISPR could be used in the body to combat a disease — in this case, a rare nerve disorder. That early data was so eye-catching it was published in the New England Journal of Medicine. But what are the next steps? The company’s CEO joins STAT to lay them out and answer your questions.
- John Leonard, M.D., president and chief executive officer, Intellia Therapeutics
- Matthew Herper, senior writer, medicine; editorial director of events, STAT (moderator)
- Chris Coburn, chief innovation officer, Mass General Brigham (sponsor speaker)